MORRISVILLE, N.C. – Q2 Solutions, a global clinical trials laboratory services organization, today announced the expansion of its genomic companion diagnostics (CDx) capabilities. This comes as a result of an agreement between Q2 Solutions – EA Genomics and Illumina, a global leader in genomics, to establish a framework for developing next-generation sequencing-based (NGS) CDx assays. The expansion of Q2 Solutions’ CDx development portfolio will further enhance the company’s wide range of end-to-end services that extend from biomarker discovery and development to the application of precision medicine through its clinical trials laboratory network.

Under the terms of the agreement, Q2 Solutions will develop NGS assays using the Illumina MiSeqDx® instrument. The MiSeqDx is the first NGS instrument to be cleared by the U.S. Food and Drug Administration (FDA) for in vitro diagnostic purposes in clinical laboratories. This alliance brings together two industry-leading companies, combining Q2 Solutions’ gl